

Sheet 1 of 1

TO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.:

**CV01382K**

SERIAL NO.:

**10/057,629**

APPLICANT:

**Harry R. Davis**

FILING DATE:

**01/25/2002**

GROUP:

**1614****U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
ms	AL	WO 95/35277	12/28/95	PCT	C07D	205/08		
	AM							
	AN							
	AO							
	AP							

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

ms	AQ	Thompson, G.R. <i>et al.</i> , "Novel lipid-regulating drugs" <i>Expert Opinion on Investigational Drugs</i> <b>9(11):2619-2628</b> (2000), XP008011782 abstract; figure 8
ms	AR	Kosoglou, T. <i>et al.</i> , "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions" <i>Atherosclerosis</i> <b>2:89</b> (2001), XP1132089 abstract
	AS	
	AT	
	AU	
	AV	

EXAMINER

DATE CONSIDERED

10/16/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.